David Schiller is a former DEA Assistant Special Agent in Charge with over 30 years of experience with the United States Drug Enforcement Administration (DEA). Beginning with his hiring as a Special Agent in 1987, he was involved in investigating some of the largest criminal drug trafficking organizations throughout the world. After serving as the Executive Assistant to the Assistant Administrator in Arlington, Virginia, Schiller was reassigned in 2009 as the Assistant Special Agent in Charge (ASAC) for the Denver Field Division. He was subsequently assigned complete supervisory oversight for the DEA’s Diversion Program. This included supervisory oversight of all of the Tactical Diversion Squads and Diversion Groups in Colorado, Utah, Montana, and Wyoming. In this capacity, Schiller led the investigation of all criminal, administrative, and civil cases affecting every one of DEA’s Registrants, including manufacturers, distributors, pharmacies, hospitals, narcotic treatment providers and doctors.
In 2015, Schiller was selected to be the Vice Chair of DEA’s Diversion Field Advisory Committee (DFAC), with ultimate responsibility for coordinating all diversion related matters for every one of DEA’s 21 Field Divisions in the United States. He ended his distinguished career by finalizing the largest administrative and civil settlement against a DEA Registrant in history—the McKesson Corporation. He retired from DEA in August 2017. Schiller’s vast experience and background were invaluable in co-founding RxDisposal and contributing to the development of its game-changing NarcX.